Pay in 4 interest-free payments of $6.83 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Expanded GLP-1 utilization is projected to cost up to $47.7 billion under a Medicare coverage model, a figure that has complicated legislative momentum
References Novo Nordisk Inc
Sustaining metabolic health through a personalized nutrition plan that pairs with your step-down from GLP-1 therapy Managing appetite changes that are often experienced and hard to manage upon discontinuing GLP-1s Promoting weight maintenance through coaching, meal planning, and physical activity recommendations Building sustainable eating habits focused on maintaining satiety with nutrient-dense meals Real results Nourish programs have delivered meaningful outcomes for patients in just 6 months greater weight loss for Nourish patients on GLP-1s (vs
TRAF3 modulation: novel mechanism for the anti-inflammatory effects of the vitamin D receptor agonist paricalcitol in renal disease
The SUMMIT trial, involving 731 individuals with HFpEF and obesity followed for a median of 104 weeks, revealed a 38% decrease in the composite endpoint of cardiovascular mortality or heart-failure deterioration events (HR: 0.62, 95%CI: 0.41-0.95, P = 0.026), driven primarily by fewer worsening heart-failure events (8.0% vs
